• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

联合检查点抑制剂和BRAF靶向药物治疗转移性黑色素瘤。

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma.

作者信息

Cooper Zachary A, Frederick Dennie T, Ahmed Zain, Wargo Jennifer A

机构信息

Division of Surgical Oncology; Massachusetts General Hospital; Boston MA USA.

出版信息

Oncoimmunology. 2013 May 1;2(5):e24320. doi: 10.4161/onci.24320.

DOI:10.4161/onci.24320
PMID:23762807
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3667913/
Abstract

The combination of BRAF-targeted agents with immune checkpoint inhibitors represents a recent advance in the treatment of melanoma, even though each of these therapeutic approaches alone has specific limitations. Increasing evidence suggests indeed the existence of a synergistic interaction between these therapeutic modalities.

摘要

BRAF靶向药物与免疫检查点抑制剂联合使用代表了黑色素瘤治疗领域的一项最新进展，尽管这两种治疗方法单独使用时都有特定的局限性。越来越多的证据确实表明，这些治疗方式之间存在协同相互作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e90c/3667913/f37abce992a7/onci-2-e24320-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e90c/3667913/f37abce992a7/onci-2-e24320-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e90c/3667913/f37abce992a7/onci-2-e24320-g1.jpg

相似文献

1
Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma.联合检查点抑制剂和BRAF靶向药物治疗转移性黑色素瘤。
Oncoimmunology. 2013 May 1;2(5):e24320. doi: 10.4161/onci.24320.
2
Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.BRAF、MEK 和 CDK4/6 抑制剂的免疫调节作用：对联合靶向治疗和免疫检查点阻断治疗黑色素瘤的意义。
Front Immunol. 2021 May 7;12:661737. doi: 10.3389/fimmu.2021.661737. eCollection 2021.
3
Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.将 BRAF/MEK 抑制剂与免疫疗法联合用于治疗转移性黑色素瘤。
Am J Clin Dermatol. 2021 May;22(3):301-314. doi: 10.1007/s40257-021-00593-9. Epub 2021 Mar 25.
4
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.抗 PD-1 检查点阻断治疗伴或不伴 BRAF 突变的转移性黑色素瘤的蛋白质组学检测。
J Immunother Cancer. 2019 Mar 29;7(1):91. doi: 10.1186/s40425-019-0569-1.
5
Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.将靶向治疗与免疫检查点抑制剂联合用于转移性黑色素瘤的治疗。
Cancer Biol Med. 2014 Dec;11(4):237-46. doi: 10.7497/j.issn.2095-3941.2014.04.002.
6
Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma.确定 BRAF 突变型转移性黑色素瘤的最佳一线治疗方案。
Expert Rev Anticancer Ther. 2020 Jan;20(1):53-62. doi: 10.1080/14737140.2020.1711737. Epub 2020 Jan 7.
7
Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.联合力量：转移性黑色素瘤中协同性免疫检查点阻断与靶向治疗的前景与风险
Cancer Metastasis Rev. 2017 Mar;36(1):43-50. doi: 10.1007/s10555-017-9656-2.
8
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.在黑色素瘤中联合阻断PD1的同时靶向MAPK和PI3K通路。
Oncoimmunology. 2016 Oct 14;5(12):e1238557. doi: 10.1080/2162402X.2016.1238557. eCollection 2016.
9
Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma.BRAF-MEK 抑制和免疫检查点抑制在转移性黑色素瘤中的综合临床试验数据总结。
Oncologist. 2019 Nov;24(11):e1197-e1211. doi: 10.1634/theoncologist.2018-0876. Epub 2019 May 7.
10
Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.在假定为 BRAF 阳性的转移性黑色素瘤患者中，接受免疫检查点抑制剂和靶向治疗的治疗模式和 BRAF 检测情况。
Melanoma Res. 2019 Jun;29(3):301-310. doi: 10.1097/CMR.0000000000000504.

引用本文的文献

1
MAP kinase kinase 1 (MEK1) within extracellular vesicles inhibits tumour growth by promoting anti-tumour immunity.细胞外囊泡中的丝裂原活化蛋白激酶激酶 1（MEK1）通过促进抗肿瘤免疫来抑制肿瘤生长。
J Extracell Vesicles. 2024 Oct;13(10):e12515. doi: 10.1002/jev2.12515.
2
Unveiling the molecular features, relevant immune and clinical characteristics of in thyroid cancer.揭示甲状腺癌中 的分子特征、相关免疫和临床特征。
Front Immunol. 2022 Sep 9;13:975787. doi: 10.3389/fimmu.2022.975787. eCollection 2022.
3
Treatment Sequencing in Advanced -Mutant Melanoma Patients: Current Practice in the United States.

本文引用的文献

1
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.BRAF 抑制与转移性黑色素瘤患者中黑色素瘤相关抗原表达增强和更有利的肿瘤微环境相关。
Clin Cancer Res. 2013 Mar 1;19(5):1225-31. doi: 10.1158/1078-0432.CCR-12-1630. Epub 2013 Jan 10.
2
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.BRAF 抑制增强了 T 细胞对肿瘤的浸润，并增强了小鼠过继免疫治疗的抗肿瘤活性。
Clin Cancer Res. 2013 Jan 15;19(2):393-403. doi: 10.1158/1078-0432.CCR-12-1626. Epub 2012 Nov 30.
3
晚期BRAF突变型黑色素瘤患者的治疗顺序：美国的当前实践
J Pharm Technol. 2018 Feb;34(1):17-23. doi: 10.1177/8755122517747089. Epub 2017 Dec 4.
4
Combined targeted therapy and immunotherapy for cancer treatment.联合靶向治疗与免疫治疗用于癌症治疗。
World J Clin Cases. 2021 Sep 16;9(26):7643-7652. doi: 10.12998/wjcc.v9.i26.7643.
5
Beyond immune checkpoint blockade: emerging immunological strategies.超越免疫检查点阻断：新兴的免疫学策略。
Nat Rev Drug Discov. 2021 Dec;20(12):899-919. doi: 10.1038/s41573-021-00155-y. Epub 2021 Mar 8.
6
The potential of BRAF-targeted therapy combined with immunotherapy in melanoma.BRAF 靶向治疗联合免疫疗法在黑色素瘤中的潜力。
Expert Rev Anticancer Ther. 2020 Feb;20(2):131-136. doi: 10.1080/14737140.2020.1724097. Epub 2020 Feb 5.
7
Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges.通过靶向缺氧肿瘤微环境改善癌症免疫治疗：新的机遇和挑战。
Cells. 2019 Sep 14;8(9):1083. doi: 10.3390/cells8091083.
8
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?血浆中程序性死亡蛋白1（PD-1）水平能否预测转移性黑色素瘤患者肿瘤浸润淋巴细胞的存在及效能？
Ther Adv Med Oncol. 2019 May 13;11:1758835919848872. doi: 10.1177/1758835919848872. eCollection 2019.
9
Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.新型 MAPK 通路抑制剂在 BRAF 突变型黑色素瘤领域的研究进展。
Clin Cancer Res. 2019 Oct 1;25(19):5735-5742. doi: 10.1158/1078-0432.CCR-18-0836. Epub 2019 Apr 16.
10
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine.癌症免疫检查点治疗反应的基因组学：对精准医学的启示。
Genome Med. 2018 Nov 29;10(1):93. doi: 10.1186/s13073-018-0605-7.
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
BRAF V600 突变型黑色素瘤的联合 BRAF 和 MEK 抑制治疗。
N Engl J Med. 2012 Nov 1;367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29.
4
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.致癌性 BRAF(V600E) 通过诱导黑色素瘤中的白细胞介素-1 促进基质细胞介导的免疫抑制。
Clin Cancer Res. 2012 Oct 1;18(19):5329-40. doi: 10.1158/1078-0432.CCR-12-1632. Epub 2012 Jul 31.
5
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.抗 PD-L1 抗体在晚期癌症患者中的安全性和活性。
N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
6
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
7
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.选择性 BRAF 抑制剂可诱导人类转移性黑色素瘤中显著的 T 细胞浸润。
Clin Cancer Res. 2012 Mar 1;18(5):1386-94. doi: 10.1158/1078-0432.CCR-11-2479. Epub 2011 Dec 12.
8
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.BRAF V600E 突变型黑色素瘤患者采用威罗菲尼治疗后生存改善。
N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5.
9
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.选择性 BRAFV600E 抑制增强了 T 细胞对黑色素瘤的识别，而不影响淋巴细胞功能。
Cancer Res. 2010 Jul 1;70(13):5213-9. doi: 10.1158/0008-5472.CAN-10-0118. Epub 2010 Jun 15.
10
Improved survival with ipilimumab in patients with metastatic melanoma.Ipilimumab 改善转移性黑色素瘤患者的生存。
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.